Oncolytic Virus Immunotherapy
Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. Thi...
Saved in:
| HerausgeberIn: | |
|---|---|
| Sonstige: | |
| Year of Publication: | 2022 |
| Language: | English |
| Physical Description: | 1 electronic resource (366 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04278nam-a2201129z--4500 | ||
|---|---|---|---|
| 001 | 993544933204498 | ||
| 005 | 20231214133213.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202205s2022 xx |||||o ||| 0|eng d | ||
| 035 | |a (CKB)5680000000037759 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/81172 | ||
| 035 | |a (EXLCZ)995680000000037759 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Marchini, Antonio |4 edt | |
| 245 | 1 | 0 | |a Oncolytic Virus Immunotherapy |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (366 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a Dear Readers, Oncolytic Viruses (OV) are self-propagating agents that can selectively induce the lysis of cancer cells while sparing normal tissues. OV-mediated cancer cell death is often immunogenic and triggers robust anticancer immune responses and immunoconversion of tumor microenvironments. This makes oncolytic virotherapy a promising new form of immunotherapy and OVs ideal candidates for combination therapy with other anticancer agents, including other immunotherapeutics. There are more than 40 OVs from nine different families in clinical development and many more at the preclinical stage. Each OV has its own unique characteristics, its pros and cons. Although herpes simplex virus is currently the lead clinical agent, a real champion among the OVs has not yet emerged, justifying the continuous development and optimization of these agents. This book, “Oncolytic Virus Immunotherapy”, summarizes the state-of-the-art and gives a comprehensive overview of the OV arena with a particular focus on new trends, directions, challenges, and opportunities. | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Clinical & internal medicine |2 bicssc | |
| 653 | |a oncolytic viruses | ||
| 653 | |a melanoma | ||
| 653 | |a immunotherapy | ||
| 653 | |a checkpoint inhibitors | ||
| 653 | |a combinatory therapy | ||
| 653 | |a reovirus | ||
| 653 | |a oncolytic virus | ||
| 653 | |a adenovirus | ||
| 653 | |a oncolytic | ||
| 653 | |a virotherapy | ||
| 653 | |a targeting | ||
| 653 | |a immunogenic cell death | ||
| 653 | |a αvβ6 integrin | ||
| 653 | |a oncolytic adenovirus | ||
| 653 | |a cancer immunotherapy | ||
| 653 | |a multi-stage | ||
| 653 | |a immunostimulatory | ||
| 653 | |a arming | ||
| 653 | |a HSV-1 | ||
| 653 | |a clinical trials | ||
| 653 | |a newcastle disease virus | ||
| 653 | |a NDV | ||
| 653 | |a cancer | ||
| 653 | |a immune checkpoint inhibitor | ||
| 653 | |a PD-1 | ||
| 653 | |a PD-L1 | ||
| 653 | |a CTLA-4 | ||
| 653 | |a type I interferon | ||
| 653 | |a herpes simplex virus | ||
| 653 | |a retargeted virus | ||
| 653 | |a tropism retargeting | ||
| 653 | |a tumor | ||
| 653 | |a checkpoint inhibitor | ||
| 653 | |a vaccination | ||
| 653 | |a antigen-agnostic vaccination | ||
| 653 | |a HER2 | ||
| 653 | |a parvovirus | ||
| 653 | |a tumor microenvironment | ||
| 653 | |a combination therapy | ||
| 653 | |a glioblastoma | ||
| 653 | |a pancreatic cancer | ||
| 653 | |a colorectal cancer | ||
| 653 | |a measles virus | ||
| 653 | |a vector engineering | ||
| 653 | |a immune checkpoint blockade | ||
| 653 | |a antitumor immune response | ||
| 653 | |a delivery | ||
| 653 | |a genetic modification | ||
| 653 | |a biomarkers | ||
| 653 | |a personalized oncolyticvirotherapy | ||
| 653 | |a class I HLA | ||
| 653 | |a immunosurveillance | ||
| 653 | |a immunoediting | ||
| 653 | |a oncogenic signaling | ||
| 653 | |a RAS | ||
| 653 | |a DNA methyltransferase inhibitor (DNMTi) | ||
| 653 | |a viral mimicry | ||
| 653 | |a epigenetic silencing | ||
| 653 | |a adoptive T cell therapy | ||
| 653 | |a CAR T cell | ||
| 653 | |a pancreatic ductal adenocarcinoma | ||
| 653 | |a vesicular stomatitis virus | ||
| 653 | |a small molecule | ||
| 653 | |a cancer immune therapy | ||
| 653 | |a cancer therapy | ||
| 776 | |z 3-0365-2549-1 | ||
| 776 | |z 3-0365-2548-3 | ||
| 700 | 1 | |a Ilkow, Carolina S. |4 edt | |
| 700 | 1 | |a Melcher, Alan |4 edt | |
| 700 | 1 | |a Marchini, Antonio |4 oth | |
| 700 | 1 | |a Ilkow, Carolina S. |4 oth | |
| 700 | 1 | |a Melcher, Alan |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:46:34 Europe/Vienna |f system |c marc21 |a 2022-05-14 21:41:54 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337792520004498&Force_direct=true |Z 5337792520004498 |b Available |8 5337792520004498 | ||